公开(公告)号：US20190255183A1

公开(公告)日：2019-08-22

申请号：US16269097

申请日：2019-02-06

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Kennett Sprogøe ,  Ulrich Hersel ,  Harald Rau ,  Thomas Wegge ,  Frank Faltinger ,  Felix Cleemann ,  Nora Kaluza ,  Ana Bernhard ,  Annette Buba ,  Tom Woods

IPC分类号： A61K47/60 ,  A61K9/00 ,  A61K38/22

摘要： The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.

公开(公告)号：US20230116746A1

公开(公告)日：2023-04-13

申请号：US17848180

申请日：2022-06-23

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Kennett Sprogøe ,  Ulrich Hersel ,  Harald Rau ,  Thomas Wegge ,  Frank Faltinger ,  Felix Cleemann ,  Nora Kaluza ,  Ana Bernhard ,  Annette Buba ,  Tom Woods

IPC分类号： A61K47/60 ,  A61K9/00 ,  A61K38/22

摘要： The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.

公开(公告)号：US11224661B2

公开(公告)日：2022-01-18

申请号：US16067111

申请日：2017-01-05

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Kennett Sprogøe ,  Harald Rau ,  Ana Bernhard ,  Ulrich Hersel ,  Felix Cleenmann ,  Thomas Wegge

IPC分类号： A61K38/00 ,  A61K47/60 ,  A61P43/00 ,  A61K38/22

摘要： The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.

公开(公告)号：US20210069339A1

公开(公告)日：2021-03-11

申请号：US16993127

申请日：2020-08-13

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Kennett Sprogøe ,  Ulrich Hersel ,  Harald Rau ,  Thomas Wegge ,  Frank Faltinger ,  Felix Cleemann ,  Nora Kaluza ,  Ana Bernhard ,  Annette Buba ,  Tom Woods

IPC分类号： A61K47/60 ,  A61K9/00 ,  A61K38/22

摘要： The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.

公开(公告)号：US20190022237A1

公开(公告)日：2019-01-24

申请号：US16067111

申请日：2017-01-05

申请人： ASCENDIS PHARMA GROWTH DISORDERS A/S

发明人： Kennett SPROGØE ,  Harald Rau ,  Ana Bernhard ,  Ulrich Hersel ,  Felix Cleenmann ,  Thomas Wegge

IPC分类号： A61K47/60 ,  A61K38/22 ,  A61P43/00

摘要： The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.